NASDAQ:PHAT
Phathom Pharmaceuticals, Inc. Stock News
$9.18
+0.0800 (+0.88%)
At Close: Apr 26, 2024
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial
04:05pm, Monday, 30'th Nov 2020
Topline results expected in second half of 2021 Topline results expected in second half of 2021
Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences
08:00am, Friday, 27'th Nov 2020
FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel trea
Phathom Pharmaceuticals to Host Virtual Investor Day
04:05pm, Thursday, 19'th Nov 2020
FLORHAM PARK, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel tre
Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
04:05pm, Friday, 13'th Nov 2020
FLORHAM PARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel tre
